Eli Lilly shoots to a new record high according to figures - | and leaves Novo in the dust
deraktionaer.de/artikel/pharma-biotech/eli-lilly-schiesst-nach-zahlen-auf-ein-neues-rekordhoch-und-zeigt-novo-die-ruecklichter-20428193.html
Pharmaceutical industry paid 15 million Swiss francs to university hospitals in 2025
bilanz.ch/unternehmen/universitaeten-und-personal-erhalten-millionen-von-pharmaindustrie/f7g1r44
Lilly is worth 6 times as much as Novo: Will the gap now widen even further?: Novo Nordisk fails with an emergency application against Lilly's advertising ...
wallstreet-online.de/nachricht/21588504-klatsche-gericht-lilly-6-mal-wert-novo-abstand-groesser
DAX falls - | Novo Nordisk, Meta, Nvidia, Porsche, Beiersdorf, Apple, Eli Lilly, Cancom
boerse-online.de/nachrichten/aktien/dax-faellt-novo-nordisk-meta-nvidia-porsche-beiersdorf-apple-eli-lilly-cancom-20425362.html
Walmart offensive: Why Novo and Eli Lilly also benefit: Walmart erweitert 2027 die Krankenversicherung: Über 250 Medikamente sind ohne Zuzahlung erhältlich ...
deraktionaer.de/artikel/pharma-biotech/walmart-offensive-warum-auch-novo-und-eli-lilly-profitieren-20416625.html
Novo stock before the test: Next price target scrapped: BMO Capital lowers its price target for Novo Nordisk to $40 as Ozempic sales in the US come under ...
deraktionaer.de/artikel/pharma-biotech/novo-aktie-vor-dem-test-naechstes-kursziel-kassiert-20415370.html
Between value trap, turnaround and dividend opportunity: What really matters at Novo Nordisk
deraktionaer.de/artikel/pharma-biotech/zwischen-value-falle-turnaround-und-dividenden-chance-was-bei-novo-nordisk-wirklich-zaehlt-20414131.html
Novo Nordisk: Will this billion-dollar deal finally bring about a turnaround?: The Danish pharmaceutical company Novo Nordisk is under pressure to revive its ...
wallstreet-online.de/nachricht/21446877-2-6-milliarden-wette-novo-nordisk-bringt-milliarden-deal-endlich-wende
Novo: Things are happening fast: Novo secures almost all global rights to HRS-1596 from Hengrui Pharma.
deraktionaer.de/artikel/pharma-biotech/novo-es-geht-schlag-auf-schlag-20409703.html
Novo share price at rock bottom - | Licensing deal causes Swedish small cap to explode
deraktionaer.de/artikel/pharma-biotech/novo-aktie-am-boden-lizenzdeal-laesst-schwedischen-small-cap-explodieren-20409567.html
80 Million Sufferers: Novo Reaches for the Multi-Billion Dollar Hair Loss Market: Novo Nordisk Seeks Growth Beyond Wegovy - | and is now targeting the hair loss ...
wallstreet-online.de/nachricht/21420822-anlegervertrauen-zerstoert-80-millionen-betroffene-novo-greift-milliardenmarkt-haarausfall
Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
cnbc.com/2026/09/25/5-things-to-know-before-the-stock-market-opens.html
Novo stock: Price targets keep falling: Novo Nordisk disappoints at its capital markets day: Analysts lower price targets.
deraktionaer.de/artikel/pharma-biotech/novo-aktie-kursziele-fallen-immer-weiter-20409286.html
Shareholder tip: Viking Therapeutics explodes - | Novo share reacts: Viking Therapeutics reports positive study data for VK2735, an obesity drug ...
deraktionaer.de/artikel/pharma-biotech/aktionaer-tipp-viking-therapeutics-explodiert-novo-aktie-reagiert-20409272.html
Viking Therapeutics after the share price explosion: Analysts see more than 100 percent potential
deraktionaer.de/artikel/pharma-biotech/viking-therapeutics-nach-der-kursexplosion-analysten-sehen-mehr-als-100-prozent-potenzial-20409316.html
Eli Lilly stock: Weight loss pill Foundayo catches up with Novo, but!: Eli Lilly: Foundayo captures every third new pill prescription
deraktionaer.de/artikel/pharma-biotech/eli-lilly-aktie-abnehmpille-foundayo-holt-gegen-novo-auf-aber--20409245.html
Novomatic stock in free fall: Capital Markets Day causes long faces: The Danes are holding a Capital Markets Day in London to kick off the new trading week.
deraktionaer.de/artikel/pharma-biotech/novo-aktie-im-freien-fall-kapitalmarkttag-sorgt-fuer-lange-gesichter-20409125.html
Novo Nordisk and Anthropic will work together to speed up drug development using AI.
For the latest Novo news, click here: Quote-NVO
Eli Lilly: Next approval - | even more pressure for Novo Nordisk: Eli Lilly receives approval for Mounjaro to reduce cardiovascular risks in type 2 diabetes.
deraktionaer.de/artikel/pharma-biotech/eli-lilly-naechste-zulassung-noch-mehr-druck-fuer-novo-nordisk-20407704.html
Gubra: AbbVie milestone - | Stock with buy signal: Gubra achieves an important milestone with AbbVie: The obesity program ABBV-295 enters Phase 2 ...
deraktionaer.de/artikel/pharma-biotech/gubra-meilenstein-von-abbvie-aktie-mit-kaufsignal-20407416.html
Novo Nordisk: Weight-loss pill continues to perform strongly - | Dividend sweetens the week for investors
deraktionaer.de/artikel/pharma-biotech/novo-nordisk-abnehm-pille-weiter-stark-dividende-versuesst-anlegern-die-woche-20407161.html
Novo CEO faces investor grilling after outlook hike soured by pipeline concerns: Novo Nordisk CEO Mike Doustdar faces investors and analysts on Wednesday under ...
bnnbloomberg.ca/business/company-news/2026/08/05/novo-ceo-faces-investor-grilling-after-outlook-hike-soured-by-pipeline-concerns/
255 percent chance: Technology group poised for a major comeback: A formerly criticized technology group shows surprisingly positive quarterly figures and a ...
deraktionaer.de/artikel/aktien/255-prozent-chance-technologiekonzern-vor-dem-grossen-comeback-20406642.html
These stocks can now profit in the fight over Ozempic's patent loss: One-third of obesity patients live in countries with the now-off-patent drug semaglutide ...
businessinsider.de/wirtschaft/diese-aktien-koennen-jetzt-im-kampf-um-ozempics-patentverlust-profitieren/
Paid articlePaywall The Danish biopharmaceutical giant Novo Nordisk raised its revenue and operating profit forecasts with its Q2 figures – but the details once again disappointed ... Show more
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
cnbc.com/2026/08/06/eli-lilly-novo-nordisk-earnings-glp1-market.html
Novo Nordisk: Analysts react - | Stock starts rebound: Subdued mood after the half-year report.
deraktionaer.de/artikel/pharma-biotech/novo-nordisk-analysten-reagieren-aktie-startet-rebound-20406356.html
Novo Nordisk: Wegovy pill coming to Germany in September: The Danish company speaks of "pleasing use" of its weight-loss pill Wegovy in the USA ...
faz.net/aktuell/wirtschaft/unternehmen/novo-nordisk-wegovy-pille-kommt-im-september-nach-deutschland-201098105.html
Weight-loss medications: Eli Lilly soaring, Novo Nordisk in freefall: Novo Nordisk expects a sales decline of up to 6 percent. Competitor Eli Lilly ...
manager-magazin.de/unternehmen/pharma/eli-lilly-us-konzern-im-hoehenflug-novo-nordisk-rechnet-mit-rueckgaengen-a-839421a1-543a-49a2-aec1-d4b8f1e13d41
Fire at will: Lockheed Martin is transforming into a munitions manufacturer: Following a major order, the order backlog of the missile division increased from ...
deraktionaer.de/artikel/deraktionaermagazin/feuer-frei-20406156.html
DAX on the rise - | Iran, Springer Nature, Schaeffler, Bitcoin, Novo Nordisk, SK Hynix, AI, Oracle
boerse-online.de/nachrichten/aktien/dax-20406109.html
Obesity battle heats up again as Novo claws way back into race with Lilly: Novo Nordisk investors have found little cause for optimism during a bruising two-year ...
reuters.com/legal/litigation/obesity-battle-heats-up-again-novo-claws-way-back-into-race-with-lilly-2026-08-03/
Novo Nordisk stock: Another setback: Novo Nordisk is struggling after a setback in cardiology and increasing price pressure in the US. Despite the challenges ...
deraktionaer.de/artikel/aktien/novo-nordisk-aktie-naechster-nackenschlag-20405951.html
Paid articlePaywall Novo Nordisk: Will the forecast be raised again?: Novo Nordisk will present quarterly figures on August 5. JPMorgan expects an increase in the annual targets.
deraktionaer.de/artikel/pharma-biotech/novo-nordisk-wird-die-prognose-erneut-erhoeht-20403700.html
EU: First diet pill to be approved: The EU drug regulatory authority is paving the way for the first diet pill in Europe. Manufacturer Novo Nordisk is thus ...
sueddeutsche.de/gesundheit/ema-zulassung-abnehmpille-li.3487757
Novo Nordisk: New data in sight: Novo Nordisk presents new data on semaglutide in MASH, a frequently undiagnosed liver disease affecting 250 million people ...
deraktionaer.de/artikel/pharma-biotech/novo-nordisk-neue-daten-in-sicht--20401295.html
Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance : Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss ...
cnbc.com/2026/05/12/hims-hers-plummets-16percent-after-first-quarter-loss-weak-guidance-.html
Novo Nordisk beats earnings expectations and the stock surges on demand for weight loss pill
qz.com/novo-nordisk-q1-2026-earnings-wegovy-pill-guidance-050626
Stock surges: More than a million Americans are using the new Wegovy weight-loss pill
manager-magazin.de/unternehmen/pharma/novo-nordisk-aktie-mit-kurssprung-ueber-eine-million-nutzer-der-wegovy-abnehmpille-a-2e38aeaa-9b92-4e42-b274-c3b51c83a424
Hims & Hers: Stock Takes a Plunge - | The Background: Hims & Hers Disappoints with Q1 Figures: Revenue Rises Only 4% to $608 Million, Margins Fall ...
deraktionaer.de/artikel/pharma-biotech/hims-hers-aktie-geht-baden-die-hintergruende-20400776.html
Nebius, Hims & Hers, Cisco & Co. Which numbers will be exciting this week!: Investors need to know about these upcoming US quarterly figures (week 20).
wallstreet-online.de/nachricht/20853510-earnings-preview-nebius-hims-hers-cisco-co-zahlen-woche-spannend-werden
Novo Nordisk after the earnings report: Here’s how analysts are assessing the situation now!
wallstreet-online.de/nachricht/20834144-haelt-kurserholung-an-novo-nordisk-zahlen-analysten-lage-ein
Novo Nordisk is starting the year with momentum and has slightly raised its forecast after a surprisingly strong first quarter ... Show more
Novo Nordisk is big-game hunting: After losing out to Pfizer on Metsera, Novo Nordisk’s CFO told Semafor the company is hunting for even bigger deals.
semafor.com/article/05/07/2026/novo-nordisk-is-big-game-hunting
Pfizer dividend stock: Expectations exceeded - | Forecast confirmed: Pfizer exceeds market expectations for revenue and profit.
deraktionaer.de/artikel/pharma-biotech/dividenden-aktie-pfizer-erwartungen-uebertroffen-prognose-steht-20400305.html
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
cnbc.com/2026/04/30/eli-lilly-lly-earnings-q1-2026.html
The US pharmaceutical company Eli Lilly presented its figures for the first quarter of the current fiscal year 2026 on Thursday before the start of trading in ... Show more
Three key trends in the biotech sector: How investors can profit: Healthcare stocks have lagged since the beginning of the year. However, biotech companies are ...
themarket.ch/makro-maerkte/drei-schluesseltrends-im-biotech-sektor-und-wie-investoren-profitieren-koennen-ld.16669
Trump admin shifts course on Medicare GLP-1 coverage: It's a blow to the administration after President Trump last year touted deals with Eli Lilly and Novo ...
axios.com/2026/04/22/trump-shelves-medicare-pilot-glp-1
Novo Nordisk stock under pressure: Competition, IPO, pill race, billion-dollar deal: How the situation is changing for Novo Nordisk
finanzen.net/nachricht/aktien/adipositas-markt-novo-nordisk-aktie-unter-druck-wettbewerb-verschaerft-sich-neue-rivalen-neue-pillen-00-15620444
Novo Nordisk and OpenAI accelerate drug research: Danish pharmaceutical company Novo Nordisk is collaborating with OpenAI to use artificial intelligence in all ...
de.euronews.com/gesundheit/2026/04/14/novo-nordisk-und-openai-beschleunigen-medikamentenforschung
Patients now have access to the strongest version yet of the sought-after GLP-1 drug. The Danish pharmaceutical giant is aiming for broad accessibility in ... Show more
Novo Nordisk vs. Eli Lilly: The battle for the diet pill has begun: Eli Lilly's diet pill Foundayo receives FDA approval. With less weight loss than Novo ...
deraktionaer.de/artikel/deraktionaerplus/novo-nordisk-vs-eli-lilly-der-kampf-um-die-abnehmpille-hat-begonnen--20398459.html
In Novo Nordisk's slipstream: Danish pharmaceutical IPO ahead?: Danish pharmaceutical company LEO Pharma is apparently planning an IPO with a focus on skin ...
deraktionaer.de/artikel/pharma-biotech/im-windschatten-von-novo-nordisk-daenisches-pharma-ipo-voraus-20397245.html
Novo Nordisk: As if that wasn't enough!: Novo Nordisk erhält FDA-Warnung und zeigt Schwäche gegenüber Eli Lilly im Adipositas-Markt.
deraktionaer.de/artikel/pharma-biotech/novo-nordisk-auch-das-noch-20396914.html
Billion-dollar obesity market: Who is waiting in the wings after Eli Lilly and Novo Nordisk?
deraktionaer.de/artikel/deraktionaerplus/milliardenmarkt-adidpositas-wer-steht-nach-eli-lilly-und-novo-nordisk-in-den-startloechern--20396730.html
Novo Nordisk shares down by double digits: Weak CagriSema results weigh on the stock.
finanzen.net/nachricht/aktien/abnehmmittel-novo-nordisk-aktie-rutscht-zweistellig-ab-cagrisema-daten-verfehlen-die-hohen-markterwartungen-15509260
Hims & Hers’ expansion plans — as well as its Super Bowl ad — have investors worried about profits
marketwatch.com/story/hims-hers-expansion-plans-as-well-as-its-super-bowl-ad-have-investors-worried-about-profits-1e60d262
Paid articlePaywall
Novo Nordisk -14% after forecasting a 5% to 13% sales drop in 2026 and a 14% Q4 profit decline
finance.yahoo.com/news/obesity-stocks-slump-novos-underwhelming-182728439.html
Novo Nordisk predicts "shocking" revenue decline - | Shares plummet: Competition in the weight-loss drug market is intensifying for the Danish company ...
faz.net/aktuell/wirtschaft/unternehmen/novo-nordisk-sagt-schockierenden-umsatzrueckgang-voraus-aktie-rauscht-ab-110831297.html
Der US-amerikanische Pharmariese Eli Lilly hat die Erwartungen an das vierte Quartal klar übertroffen. Und auch bei der Prognose liegt das Unternehmen deutlich ... Show more
Novo Nordisk stock plunges 17 percent after gloomy forecast for 2026: The stock plummeted after the company projected a decline of five to thirteen percent in ...
de.euronews.com/business/2026/02/04/novo-nordisk-aktie-sturzt-nach-truber-prognose-fur-2026-um-17-prozent-ab
Wegovy-maker Novo Nordisk warns 'unprecedented' price pressure to hit sales: Novo Nordisk's shares tumbled on Wednesday, knocking nearly $50 billion in value ...
reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-shock-2026-guidance-points-obesity-battle-heating-up-2026-02-04/
Pfizer: Good figures, new data - | Challenge to Novo Nordisk and Co: Pfizer exceeds Q4 expectations; confirms 2026 guidance.
deraktionaer.de/artikel/pharma-biotech/pfizer-gute-zahlen-neue-daten-kampfansage-an-novo-nordisk-und-co-20394726.html
These stocks promise huge profits - | in a $100 billion market: Novo Nordisk and Eli Lilly lead the weight-loss therapy market, while new competitors are ...
boerse-online.de/nachrichten/aktien/fette-gewinne--20393160.html
Key FactsWegovy Now Available as Daily Weight-Loss Pill
Jan 5, 2026 · Reading time: ~30 sec.
Summary created with AI assistance · Source: cnn.com
Summary created with AI assistance · Source: cnn.com
- The 1.5 mg starter dose of Wegovy is now accessible as a daily pill with a prescription.
- For self-paying patients, the pill is generally less expensive than the weekly injection priced at $349 per month.
- Wegovy also reduces the risk of heart attack and stroke in overweight adults with established heart disease.
- Clinical trials indicate the pill produces comparable weight loss and side effects to the injectable version.
Stock market dates 2026: Vacation ban applies to investors during these weeks: Stock market year 2026: Important dates for investors focusing on quarterly ...
boerse-online.de/nachrichten/geld-und-vorsorge/boersentermine-2026-in-diesen-wochen-gilt-fuer-anleger-urlaubssperre-20393390.html
BUY ✅ HOLD ✅ CASH IN ✅ Up to 20% return - | snag top dividends every month 📈 This and much more in the new issue of DER AKTIONÄR 03/2026 ➡️ DER AKTIONÄR - | Börsenmedien AG
Up to $618 million: Amgen bets on Cologne biotech company: Amgen buys Dark Blue Therapeutics and closes deal with DISCO Pharma for up to $618 million for cancer ...
deraktionaer.de/artikel/pharma-biotech/bis-zu-618-millionen-dollar-amgen-wettet-auf-koelner-biotech-firma-20392966.html
Weight loss revolution: The post-Ozempic era begins: The pills are coming: New weight loss products promise easier use at lower costs - | but they have one ...
op-online.de/welt/abnehmrevolution-die-aera-nach-ozempic-beginnt-zr-94099470.html
Why Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise': Pfizer stock tumbled Tuesday after the drugmaker missed Wall Street's earnings forecast following ...
investors.com/news/technology/pfizer-stock-pfizer-guidance-2026/
Pharma: Weight Watchers aims to finally gain weight again with diet pills: Following its insolvency proceedings, the US corporation is restructuring ...
handelsblatt.com/technik/medizin/pharma-weight-watchers-soll-mit-abnehmpillen-endlich-wieder-zunehmen/100179904.html
Paid articlePaywall
Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks: Negotiations that could have led to coverage for weight-loss drug Wegovy under ...
globalnews.ca/news/11556153/wegovy-price-negotiations-canada/
Investment: Undervalued despite the rally - | five attractive quality stocks: In the DAX, Stoxx 50, and Dow Jones, many stocks are overpriced after the stock ...
handelsblatt.com/finanzen/maerkte/aktien/geldanlage-unterbewertet-trotz-rally-fuenf-attraktivequalitaetsaktien/100177737.html
Paid articlePaywall 4TEEN4: Extreme situation cardiogenic shock - | This company is working on a game changer
deraktionaer.de/artikel/pharma-biotech/4teen4-extremsituation-kardiogener-schock-diese-firma-arbeitet-an-einem-gamechanger-20390988.html
Paid articlePaywall